Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
286.08B
Market cap286.08B
Price-Earnings ratio
21.05
Price-Earnings ratio21.05
Dividend yield
2.20%
Dividend yield2.20%
Average volume
3.00M
Average volume3.00M
High today
$142.18
High today$142.18
Low today
$140.96
Low today$140.96
Open price
$141.96
Open price$141.96
Volume
1.36M
Volume1.36M
52 Week high
$170.46
52 Week high$170.46
52 Week low
$121.57
52 Week low$121.57

NVS News

TipRanks 3d
Novartis announces positive CHMP opinion for Cosentyx

Novartis (NVS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending ma...

Benzinga 4d
Why Is Novartis Stock Trading Higher Today? - Novartis - Benzinga

...

Why Is Novartis Stock Trading Higher Today? - Novartis - Benzinga
Benzinga 4d
Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform

Novartis AG (NYSE:NVS) announced Thursday it terminated a mid-stage trial for an experimental amyotrophic lateral sclerosis (ALS) drug. However, the Swiss phar...

Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform

Analyst ratings

53%

of 30 ratings
Buy
36.7%
Hold
53.3%
Sell
10%

More NVS News

Investor's Business Daily 5d
Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares

Technology Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares Licensing Novartis (NVS) added another failure to its docket Wednes...

Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares
Seeking Alpha 5d
Novartis scraps ALS therapy after mid-stage trial setback

Novartis (NVS) has discontinued the development of VHB937/lifonebart, an experimental therapy for a fatal nervous system disease known as amyotrophic lateral sc...

Novartis scraps ALS therapy after mid-stage trial setback
Nasdaq 6d
Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson (Symbol: JNJ) is the #10 broker pick, on average, out of the 30 stocks m...

Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.